Erasca, Inc. (ERAS) 股票分析

公司概述

Erasca, Inc. operates as a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing targeted therapies specifically for patients suffering from RAS/MAPK pathway-driven cancers. Within the broader healthcare sector, the company functions specifically within the biotechnology industry, a domain characterized by high regulatory hurdles and significant capital requirements for drug development. The firm currently maintains a market capitalization of $5.40B, employs a workforce of 103 individuals, and reports no available annual revenue figures in the provided data. The substantial market capitalization relative to the lack of reported revenue indicates that the company's valuation is driven primarily by investor expectations regarding the potential success of its product pipeline rather than current cash-flow generation from sales.

财务健康

The company reports a net income of $-124,546,000 and an EBITDA of $-128,298,000 for the trailing twelve months, while specific revenue data is not available, creating a significant gap that highlights a cost structure dominated by research and development expenditures typical of early-stage biotechnology ventures. Free cash flow stands at $-66,761,124, which signifies that the company is currently burning through cash reserves to fund its operations and clinical trials, thereby limiting immediate financial flexibility without further capital raising. All three key margin metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or that non-recurring costs have entirely offset any operational earnings in the reported period. On the balance sheet, the company holds $276.08M in cash against $47.14M in debt, resulting in a debt-to-equity ratio of 14.50, which suggests a highly leveraged position relative to equity, though the absolute debt load is manageable given the cash buffer. The current ratio is listed at 10.04, a figure that theoretically indicates exceptionally strong short-term liquidity and the ability to cover short-term obligations multiple times over, though such a high figure in a cash-burning firm often reflects a temporary state before cash reserves deplete. Return on Equity is -33.3% and Return on Assets is -18.3%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and in total assets, a common characteristic for clinical-stage firms but one that necessitates efficient capital deployment to avoid insolvency.

估值评估

The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed at -32.06, implying that the market is pricing in future earnings expectations that could eventually turn the current negative trajectory positive. The price-to-book ratio is 15.17, a metric that indicates the market is valuing the company at a significant premium over its tangible book value, reflecting the high valuation placed on the intangible assets of its drug pipeline. The price-to-sales ratio and EV/EBITDA are both unavailable or negative at -40.27, suggesting that traditional multiple-based valuation models are not applicable until the company generates positive revenue and EBITDA. The stock has exhibited extreme volatility within the past year, trading between a 52-week low of $1.01 and a high of $18.20. Without a specific current price provided in the data to calculate the exact percentage, the stock's position relative to this wide range demonstrates high sensitivity to clinical trial results and market sentiment. The beta value is 1.05, which indicates that the stock's price volatility moves slightly more in tandem with the broader market index compared to a standard stock with a beta of 1.0.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both not available, preventing a direct comparison of earnings growth rates versus revenue growth rates due to the lack of historical baseline data. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm currently reinvests all available cash flow back into research, development, and clinical operations rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies in the clinical stage, where capital preservation and pipeline advancement take precedence over income generation. Consequently, the overall growth and income profile is defined by a reliance on future product approvals to drive valuation, with no current contribution to shareholder income through dividends or earnings expansion.